Incyte's Trial Success Paves Way for Expanded Lymphoma Treatment

Incyte Corporation INCY has announced promising results from its late-stage clinical trial, which demonstrated that a combination of tafasitamab and lenalidomide, when added to the R-CHOP chemotherapy regimen, significantly extended progression-free survival in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). This result marks a significant milestone for Incyte as it plans to seek expanded regulatory approval from the U.S. Food and Drug Administration for first-line use of this combination therapy in the first half of 2026.

The trial, which involved approximately 900 adult patients, showed that those receiving the combination therapy experienced longer periods without disease progression compared to those treated with the standard R-CHOP regimen alone. This finding is particularly noteworthy given that DLBCL is the most common type of non-Hodgkin lymphoma in adults, accounting for roughly 40% of cases worldwide. In the United States US, around 24,000 people are diagnosed with DLBCL each year, highlighting the potential impact of this new treatment option.